| | POLISH FINANCIAL SUPERVISION AUTHORITY | |
| |
| | | UNI - EN REPORT No | 15 | / | 2014 |
| | |
| | Date of issue: | 2014-04-07 | | | | | | | | |
| | Short name of the issuer | | | | | | | |
| | KRKA | |
| | Subject | | | | | | | | | | |
| | Decision of the Patents Court in London relating to Esomeprazole | |
| | Official market - legal basis | | | | | | |
| | Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
| |
| | Unofficial market - legal basis | | | | | |
| | Contents of the report: | | | | | | | | |
| | Krka d.d., Novo mesto (hereafter referred to as Krka) is informing the public that Krka has received the decision of the High Court of Justice, Patents Court in London in the tort proceeding between by AstraZeneca AB, Švedska and AstraZeneca UK Limited (hereinafter collectively referred to as AstraZeneca) in which Krka and its UK partner requested damages because of interim injunction which prevented sales of Krka’s Esomeprazole in the UK between mid-2010 and mid-2011, for alleged infringement of AstraZeneca's patent EP 1 020 461. Krka will receive damages and legal costs in an amount of approx. 21,000,000 EUR.
The decision is not final. AstraZeneca can file an appeal against the decision.
| |
| | Annexes | | | | | | | | | | |
| | File | Description | |
